What's Happening?
Proteolysis-targeting chimeras (PROTACs) are advancing from scientific novelty to clinical application, requiring new development strategies. While PROTACs have shown potential in degrading disease-relevant proteins, their success now depends on integrating
chemistry, pharmacology, safety, and manufacturability early in development. The focus is shifting from proving the mechanism to ensuring clinical viability, with challenges in exposure, selectivity, and manufacturing. The field is maturing, demanding a balanced optimization approach across various parameters to translate promising degraders into viable therapies.
Why It's Important?
The maturation of PROTACs represents a pivotal shift in drug discovery, expanding the scope of therapeutically addressable targets. As the field progresses, the ability to translate scientific breakthroughs into clinically viable therapies becomes crucial. This transition could redefine drug development workflows, emphasizing early integration of various disciplines to address translational challenges. Successful adaptation of these strategies could lead to more effective treatments for previously 'undruggable' conditions, impacting pharmaceutical innovation and patient outcomes.
